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Abstract 
 
In this paper, we aim to focus on false positive results in the evaluation of thyroid aspirations, 
covering cystic, inflammatory, follicular and oncocytic lesions, papillary carcinoma, and 
medullary carcinoma of thyroid. The recently described entity, “noninvasive follicular thyroid 
neoplasm with papillary-like nuclear features” (NIFTP), is also discussed  detailing the impact 
of its introduction on  the sensitivity and specificity of thyroid FNA, as well as the use of 
molecular tests for diagnostics. Medicolegal issues in relation to current practice in English 
law are also described. 
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Introduction 
Fine-needle aspiration cytology (FNAC) is widely accepted as a rapid, cost-effective, and safe 
method for the diagnosis of thyroid nodules although it is accepted that false positive 
diagnoses of malignancy do occur. 1,2 The positive predictive value of FNAC for malignancy 
according to The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) is 97%-
99%, and this figure includes NIFTP tumours,  the sensitivity and specificity of thyroid 
FNAC have been reported as 65%-99% and 72%-100%, respectively. 1 – 4 The Royal College 
of Pathologists in its 2016 Guidance on the Reporting of Thyroid Cytology Specimens also 
indicates from review of the published literature a sensitivity for malignancy typically of 65% 
to 98%, a specificity of 76-100%, and a false positive rate of 0-5%5. The results of fifth UK-
wide national audit of thyroid surgical practice conducted by The British Association of 
Endocrine and Thyroid Surgeons (BAETS) shows a false positive rate for Thy5 (equivalent to 
Bethesda Category VI) of around 2%. The BAETS National Audit does not include non-
operated cases. The rates of cancer diagnosis of all types recorded in The BAETS Fifth 
National Audit were Thy 5 (equivalent to Bethesda Category VI) 97.9% (1,414 / 1,444 cases) 
and Thy 4 (equivalent to Bethesda Category V) 74.4% (623 / 837 cases)6.  
The main goal of thyroid FNAC is to determine the presence or absence of a neoplasm, then 
to diagnose any neoplasm present as benign or malignant, and finally to determine the exact 
type of tumour present. 2,4,7 Thyroid FNAC can be used as a ‘rule in’ test most of the time for 
papillary carcinoma but for follicular and medullary carcinomas for example, thyroid 
cytology functions as a ‘rule out’ test much of the time. In adults, FNA has been established 
in large reviews as a useful test in the differentiation of a thyroid nodule as malignant or 
benign. 8,9 Many research groups have found that FNA in children and adolescents is a highly 
sensitive and accurate test in differentiating benign from malignant nodules. 10 - 13 In a study 
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by Stevens et al, sensitivity and specificity of this test in the pediatric population were 94% 
(95% confidence interval [CI], 86%-100%) and 81% (95% CI, 72%-91%). 14However, 
misdiagnosis of cancer by cytopathology examination has remained one of the most 
problematic issues in thyroid pathology.  The rate of false-positive FNAC for thyroid nodules 
has been reported as 2%-10%, 3,15 compared with rates of 0%-14% for false-negative results 
16,17.  The mean risk of malignancy for lesions classified as suspicious for malignancy and 
malignant in TBSRTC is 75.2% and 98.6%, respectively. Overdiagnosis resulting from 
cytopathology results may lead to excessive treatment, specifically, unnecessary 
thyroidectomy and also other treatments. Considering the current trend towards conservative 
treatment for patients with thyroid carcinoma, false positivity can be as  problematic as  false 
negativity. In particular, thyroid surgeons could face the experience of performing 
unnecessary surgery in patients with false positive results.3 In this paper, we discuss the main 
causes of false positive in thyroid FNAC (Table 1). We divided the lesions in two groups: 
cystic and solid. 
 
Cystic Lesions 
  The term cystic thyroid nodule is used to describe any fluid-filled thyroid nodule.  
Approximately 15% to 25% of solitary thyroid nodules are cystic or predominantly cystic, 
and most nodules are benign. 18 Despite the good performance of FNAC in the evaluation of 
thyroid nodules, its accuracy is lower in cystic lesions than in solid masses. 19- 21 Cystic lesions 
of the thyroid constitute a particular problem in FNA especially because malignant neoplasms 
may also present as a simple or complex cyst. The potential for false-negative diagnosis of 
cystic thyroid malignant neoplasms is well demonstrated in the literature.1,2,4 However, cystic 
lesions also can be a cause of false positive diagnosis. Cyst-lining cells are follicular or 
mesenchymal cells with reactive changes, associated with cystic degeneration of thyroid 
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nodules. The reactive cyst lining cells have distinct cytoplasmic borders, loose to dense 
granular cytoplasm, occasional exaggerated unipolar/ bipolar cytoplasmic processes (Figure 
1). Nuclei can be large, round to oval but always with regular borders, and may show grooves 
and hypochromasia with distinct nucleoli. 2,4,22 The spindle-shaped morphology of the cells, 
resembling reparative epithelium in cervical, bronchial and gastrointestinal cytological 
specimens is useful in distinguishing these cells from papillary thyroid carcinoma (PTC). In 
rare instances these cells are more packed, less elongated and with overlapping, making it 
more difficult to rule out PTC. According to TBSRTC, a diagnosis of atypia of undetermined 
significance (AUS)/ follicular lesions of undetermined significance (FLUS) is more 
appropriate. 
Cystic changes and degenerative processes may cause florid atypia which is a significant 
cause of false positive and negative results. In a study on thyroid cysts containing atypical 
cells, among 12 selected cytological features, intranuclear pseudoinclusions, papillary 
microarchitecture, nuclear crowding and mitoses were the ones suggesting carcinoma. 22 
Because of some studies suggesting that atypical cells can be the cause of false positive repeat 
FNA over  a short period of time, the previous edition of TBSRTC suggested to wait at least 3 
months before repeating  the  FNA, however, the 2017 edition of TBSRTC did not accept the 
evidence for the effect of early repeat FNA on increased atypical results2. Histological 
alterations can occur following thyroid FNAC, such as infarction, necrosis and vascular 
changes. These alterations are not frequent but can cause false-positive  histological 
diagnosis. Thin needles and a non-aspiration FNAC technique can reduce these findings. 23 
Squamous metaplasia can be also a source of a false-positive diagnosis. Cystic lesions of 
congenital rest origin, such as intrathyroidal lymphoepithelial cysts of probable branchial cleft 
origin are often sources of intrathyroidal squamous cells. The FNA specimens from these 
cysts consist of macrophages, neutrophils, and a mucoid or proteinaceous background 
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admixed with squamous cells. 24 In some cases, the squamous metaplasia can be so extensive 
that may lead to the suspicion of PTC with squamous differentiation. 24 If atypical cytologic 
features are appreciated in a smear with a mixed pattern (few squamous cells, follicular cells 
and colloid, plus/minus inflammatory cells and macrophages), reactive squamous metaplasia 
arising in the background of cystic change or Hashimoto thyroiditis is the most likely 
explanation. 24  
In some situations, performing a cell block in a cystic aspirate can convert non-
diagnostic results into a satisfactory sample, as well avoiding false-positive results.25 
 
 
Inflammatory Lesions 
Inflammatory lesions of thyroid include acute, granulomatous thyroiditis and 
lymphocytic thyroiditis (Hashimoto’s thyroiditis). FNA is indicated in these situations when 
by palpation or imaging a nodule is identified. 
 
Acute suppurative thyroiditis 
Tenderness, fever, debility and high ESR should enable a confident clinical diagnosis 
of acute thyroiditis, but the condition may resemble a rapidly growing anaplastic carcinoma, 
since the latter  is frequently necrotic and accompanied by neutrophils. Sometimes in 
anaplastic carcinoma, the inflammatory infiltrate is so florid that it obscures the malignant 
cells. The malignant cells may also have a histiocytic or fibroblastic appearance, enhancing 
the possibility of confusion with acute suppurative thyroiditis. Therefore, in the presence of 
histiocytes and neutrophils, we need to give a differential diagnosis, but the definitive 
diagnosis of anaplastic carcinoma requires the identification of clearly malignant cells. The 
presence of bacteria (MGG, Gram stain) in thyroiditis or bizarre giant cells and obvious 
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features of malignancy in carcinoma allows a correct diagnosis. The response to antibiotics 
should be dramatic in infective lesions. 
 
Granulomatous Thyroiditis 
Granulomatous reaction due to subacute thyroiditis (De Quervain’s thyroiditis) is 
much more common than other granulomatous conditions of thyroid such as fungal infections, 
tuberculosis or sarcoidosis, 4,26 comprising nearly 3-6% of all thyroid lesions. 26 - 28    
Localized anterior neck pain, glandular tenderness and diffuse pain in the ears are the usual 
clinical features. Although the diagnosis is usually made clinically, FNAC plays a pivotal role 
in differentiating De Quervain’s thyroiditis from other lesions mimicking it, specifically 
malignancies and other forms of thyroiditis.29 Numerous neutrophils, and mononucleated 
inflammatory cells are present in early stage while an increased amount of fibrous stromal 
fragments and abundant multinucleated giant cells mixed with lymphocytes are much more 
prominent in the later stages. Follicular epithelial cells are usually scanty, frequently have 
small vacuoles in the cytoplasm and may show some degree of atypia; in addition, epithelioid 
histiocytes may remain unrecognized and can be interpreted as atypical cells, especially in 
cases with smearing artefacts  (Figure 2). Cell debris in the background of smears can also 
simulate necrosis (Figure 3). Recognizing the cytomorphological details of multinucleated 
giant cells, epithelioid histiocytes, and fibrotic degenerate stromal fragments in the busy 
background created by acute-chronic inflammation and debris is important to prevent false 
positive diagnosis in this entity. 4,26   
 
Lymphocytic Thyroiditis/Grave´s Disease 
Hashimoto’s thyroiditis is a well-established entity with typical clinical and 
cytomorphological findings.  In the initial phase, there is antibody-mediated destruction of 
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thyroid follicles and lymphocytic infiltration. In the chronic phase, there will often be only 
minimal residual and atrophic follicles with fibrosis of the thyroid parenchyma.30 
Polymorphic lymphoid infiltration, plasma cells, micro-tissue fragments with  germinal center 
formation, and oncocytic changes in the epithelium are typical features. Pitfalls in the 
cytological evaluation vary depending on the stage of the disease as well as accompanying 
Graves’ disease. The “cellular stage” is composed of a proliferation of oncocytes. Oncocytic 
change leads to some nuclear atypia: nuclear enlargement, fine chromatin texture, prominent 
nuclear membranes and macronucleoli (Figure 4). Nuclear grooves and even pseudoinclusions 
are described in Hashimoto’s thyroiditis. 3,4,31 Not only these changes but also squamous 
metaplasia of thyroid follicular epithelial cells in “fibrotic stage” may give a misleading 
impression as suspicious for malignancy. Indeed, Hashimoto’s thyroiditis is one of the most 
common causes of false positive PTC diagnosis. 3,4,31 In a recent study, involving 3048 cases 
of PTC it was detected in 48 false positive cases.3 Among these 48 patients with false-positive 
cytology results, final surgical specimens were positive for thyroiditis in 26 (54.2%), which is 
a very high rate compared with the rate of pathological thyroiditis (9.4%) among the total 
number of patients finally diagnosed as PTC. When cases of clinical thyroiditis were 
included, the ratio was further increased. These findings support the possibility that thyroiditis 
is a risk factor for false positivity of FNAC.3 On the other hand, PTC arising in Hashimoto’s 
thyroiditis” is not rare; and a cytomorphologically clear-cut PTC should not be downgraded as 
‘atypia’ or ‘suspicious for malignancy’ because of the presence thyroiditis in the background. 
Besides, “Warthin’s variant of PTC” should also be remembered and excluded in an aspirate 
composed of oncocytic cells and lymphocytes. In a study by Harvey et al., it was shown that 
epithelial groups of Hashimoto’s thyroiditis are usually infiltrated by lymphocytes in contrast 
to the epithelial clusters of PTC, which are usually devoid of lymphocytes.31 
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Sampling dominant nodules in Hashimoto’s thyroiditis may produce aspirates mainly 
composed of oncocytes in macrofollicles, microfollicles, trabeculae, or solid sheets that could 
be interpreted as an oncocytic follicular neoplasm leading to a lobectomy. 4,31 Careful search 
for the lymphocytic component in the background is necessary; even if it is lacking, in the 
appropriate clinical setting TBSRTC recommends to report such cases AUS/FLUS instead of 
“Follicular neoplasm/Suspicious for follicular neoplasm (FN/SFN)”.2 Aspirates in the “florid 
lymphoid phase” may be entirely composed of lymphocytes and may be confused with  low-
grade lymphoma (Figure 5). Detailed clinical findings and flow cytometry would be very 
useful in this differential diagnosis. 32  Serology testing for thyroid autoantibodies should be 
part of the workup of cases of lymphocytic thyroiditis and in presence of a positive 
autoantibody test in an atypical cytology the risk of malignancy differs if the test is negative. 
Graves’ disease is a common cause of hyperthyroidism and reported rates of 
malignancy vary between 2.3-19%.4 Oncocytic and/or non-oncocytic thyroid follicular 
epithelial cells,large amounts of flame cells, watery colloid, lymphocytes, and rarely 
granulomas are seen in aspirations. 33 Cytological findings are challenging, especially after 
treatment. 34 Distinctive pleomorphism, hyperchromasia, elongation of nuclei with occasional 
grooves and inclusions can be seen in this entity. 4,33,34 To diagnose PTC in the background of 
Graves´ disease, all the PTC criteria should be present in the aspirates. 33  
 
Follicular-pattern Lesions 
The main diagnostic challenge of FNA is what to do with the finding of follicular cells 
on FNA cytology. 35 The range of follicular lesions of the thyroid includes  adenomatoid 
nodule (AN), follicular adenoma (FA),  and follicular carcinoma (FC) with  the presence or 
absence of a capsule defining the histopathological differences (AN vs. FA) and 
capsular/vascular invasion (FA vs. FC). 4,36 For these lesions, by definition, cytopathology is a 
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screening test rather than a diagnostic test. FN/SFN is the category covering these lesions in 
TBSRTC.2 Apart from AN, FA and FC, follicular variant of papillary carcinoma (FV-PTC), 
poorly differentiated carcinoma, parathyroid adenoma, dyshormonogenetic goitre, and 
thyroiditis are the other entities that could be considered in the differential diagnosis in  this 
category. Follicle-pattern lesions can appear in cytology as micro or macrofollicles. 
Microfollicles are composed of less than 15 overlapping thyroid follicular epithelial cells 
forming a circle that is at least two-thirds complete with or without intraluminal dense colloid. 
37 Macrofollicles, form small or large flat sheets/groups or even rows but not circles; 
overlapping is not their character. Microfollicles can be observed as primary pattern- scattered 
isolated single microfollicles- or in groups as secondary pattern. In bloody smears, the 
presence of clots can create pseudo microfollicular appearance and we should be careful not 
to call the crowded small groups in clot microfollicles  (Figure 6). In this situation, observing 
microfollicles out of the clot may be helpful.2,4 Sampling from microfollicular/cellular areas 
of benign follicular nodules may trigger a diagnosis of FN/ SFN and give rise to  unnecessary 
surgery. However, the main goal of cytopathology in these lesions is not to establish an 
absolute diagnosis but the correct management for the patient. Follicular variant PTC (FV-
PTC) must be excluded from FN/SFN category. The nuclei of follicular lesions/neoplasms are 
expected to be round and rather hyperchromatic with coarse granular chromatin, which might 
be slightly larger than regular thyroid follicular epithelial cells. It is well known that some of 
the FVPTCs do not show the characteristic nuclear features of PTC and may present with 
subtle nuclear changes. The cytologic diagnosis of malignancy in these cases is based 
primarily on the nuclear features with or without the overall architectural information. The 
introduction of the entity NIFTP as mentioned before creates the possibility of false positive 
diagnosis  of PTC on cytology specimens. 38-41 This entity and its impact on routine FNA 
practice are discussed later. 
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Intrathyroidal parathyroid adenoma and dyshormonogenetic goitre are the other 
entities that are characterized by a microfollicular pattern and lack of colloid. Noting presence 
of a clinical history of congenital hypothyroidism in  dyshormonogenetic goitre and 
performing PTH assays on needle rinses or immunohistochemical studies on cell blocks are 
good approaches to the differential diagnosis. Microfollicles without intrafollicular colloid 
(empty follicles) and presence of large bizarre cells is highly suggestive for 
dyshormonogenetic goiter. Parathyroid adenomas show a prominent vascular network and 
neuroendocrine type chromatin. Epithelial clusters or microfollicles may predominate in the 
aspirates and many bare nuclei are commonly present in the background. Particularly for 
aspirates from thyroidectomy beds, which show a microfollicular pattern, parathyroid tissue 
should be remembered in the differential diagnosis. 42   
Hypercellularity, a microfollicular pattern, prominent atypia, and bizarre cells with 
big-dark nuclei can also be seen in thyroid after radiation (radioactive iodine/ external 
radiation beam therapy) and/ or some medical therapies (anti-thyroid, chemotherapy) and may 
mimic malignancy. 4, 34 Clinical information about previous therapy is fundamental for the 
correct diagnosis when these morphological findings are present. 
PTEN hamartoma tumour syndrome (PTHS) encompasses different syndromic 
disorders which are all associated with a germline mutation (point mutation or 
deletion/duplication) of the tumour suppressor gene PTEN, including Cowden Syndrome. 
Recent data suggest that thyroid disease in patients with PTEN mutation occurs at an early 
age in life. The high percentage of thyroid lesions at the first ultrasound after diagnosis of 
PTEN mutation underlines the importance of screening for thyroid disease immediately after 
diagnosis of PTHS. The high percentage (75%) of thyroid pathologies in total emphasizes the 
importance of a structured follow-up, including FNAC. Most of these lesions are follicular-
pattern lesions. 43  
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Oncocytic Lesions 
Oncocytic lesions of thyroid present a spectrum from hyperplasia / metaplasia to 
neoplasia. Oncocytic/Hurthle cells have abundant, finely granular, dense eosinophilic 
cytoplasm, and centrally placed large round nuclei with prominent nucleoli. Not only does it 
describe a phenotype but it also identifies a unique biologic process: the proliferation of 
morphologically abnormal mitochondria in the cytoplasm of neoplastic cells. 44 Oncocytes and 
hyperfunctioning thyroid follicular epithelial cells may look similar at first glance; however, 
oncocytes have defined cell borders and granular cytoplasm. Pitfalls in the diagnosis of 
oncocytic lesions are quite similar to those seen in follicular lesions and can be summarized in 
three parts; -the differentiation between non-neoplastic and neoplastic lesions, -true oncocytic 
neoplasia versus oncocytic variant of other thyroid malignancies and oncocytic adenoma 
versus carcinoma which is not possible by cytology. Background colloid, inflammation and 
the ratio of oncocytic cells are important to identify non neoplastic nodules and to avoid false-
positives; the aspirates from oncocytic neoplasms maybe composed of >70% oncocytes. 45 In 
a series of 70 cases of thyroid nodules with Hurthle cells (HC), Kasper et al. 46 described 4 
false-positive cases of Hurthle Cell Neoplasia (HCN). Three cases were multinodular goiter 
with nodules composed predominantly by HCs and one case was a Hashimoto thyroiditis. 
Overall high cellularity, scant or sticky colloid and >90% HCs on FNAB are consistently seen 
in a neoplastic HC process, although are not sufficient to distinguish benign from malignant. 
In instances when high cellularity and a high percentage of HCs are associated with the 
presence of abundant colloid and/or a background of Hashimoto’s thyroiditis, these lesions 
are better classified as follicular lesions or HCs of uncertain significance rather than as 
suspicious or positive for HCN. A finding of prominent nucleoli is more commonly seen in a 
neoplastic process. However, the presence of prominent nucleoli on a background of 
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Hashimoto’s thyroiditis is to be interpreted with caution in order to avoid overdiagnosing 
these nodules as neoplastic. The follicular and oncocytic variants of PTC also remain 
diagnostic challenges. 46  
 
Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFT-
P) 
Recently a subset of encapsulated FV-PTC with a very indolent clinical course was 
defined when treated with lobectomy alone (without radioactive iodine treatment). This new 
entity was called “noninvasive follicular thyroid neoplasm with papillary-like nuclear 
features” (NIFTP) and there are specific criteria for this diagnosis.38 Since this lesion is 
considered “a very low risk malignancy” but it shares some cytological findings with PTC, it 
should also be considered a potential cause of false positive results in thyroid FNA.39 The 
challenge posed by NIFTP is especially with the “suspicious for malignancy” and 
“malignant” categories, where the FNA diagnosis can frequently prompt initial total 
thyroidectomy, but where more conservative management (i.e. lobectomy) would be 
preferable if the histological diagnosis proves to be NIFTP. 38 The effects of reclassification 
of some cases of FV-PTC as NIFTP on the risk of malignancy (ROM) associated with the 
categories of TBSRTC are minimal if strict criteria are used. 39,40,41  
To avoid false positive FNAC, the six criteria for PTC recommended by TBSRTC are 
required for a definitive diagnosis of malignancy: enlarged nuclei, oval or irregularly shaped 
and sometimes moulded nuclei, longitudinal nuclear grooves, intranuclear cytoplasmic 
pseudoinclusions, pale nuclei with powdery chromatin, and marginally placed micronucleoli. 
2,41 A recent study involving approximately 500 cases showed that the presence of 3 or more 
intranuclear pseudoinclusions is one of the best criteria to discriminate PTC from lesions 
classified as suspicious at cytology.41 Samples from FVPTC’s demonstrate a microfollicular 
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growth pattern with varying degrees of nuclear alterations (nuclear enlargement, membrane 
irregularities, and chromatin clearing). If the latter nuclear alterations associated with FVPTC 
are abundantly present in cytology samples, an accurate presurgical diagnosis of PTC may be 
rendered. Conversely, when these nuclear alterations are found in few cells, the specificity for 
malignancy also decreases because these alterations are observed in benign reactive 
conditions. In the explanatory notes on FVPTC, the TBSRTC states “current practice suggests 
that only the cases with definitive nuclear features of PTC should be diagnosed unequivocally 
on FNA”.2 Because the threshold for making a cytopathological diagnosis of malignancy lies 
in the balance between the sensitivity to diagnose low-grade PTCs such as FVPTC and the 
specificity to minimize the risk of a false-positive diagnosis, the focus has shifted toward the 
interpretation of “definitive nuclear features”.41,47  
Molecular correlation is also indicated since in many studies the NIFTP group of lesions show 
“RAS-like” mutations and BRAF V600E mutations are almost non existent  when the criteria 
for NIFTP are strictly applied 41. (See further discussion in the molecular section).   
 
Papillary thyroid carcinoma 
 Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy. The 
pathological diagnosis and classification of PTC is usually based on the microscopic 
appearance of biopsy specimens. Misdiagnosis of PTC by cytopathological methods has 
remained one of the most problematic issues in pathology.3 The pitfalls related to the 
cytological diagnosis of PTC should be analyzed in two parts concerning pattern and nuclear 
features. It is well known that nuclear details are the core of PTC diagnosis: “enlargement, 
oval shape, membrane irregularity, clearing, longitudinal grooves, intranuclear 
pseudoinclusions. Among the nuclear features of PTC, the most specific is intranuclear 
pseudoinclusions.41 One should be strict to define intranuclear pseudoinclusions, since their 
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presence makes the aspirate at least suspicious for PTC. Intranuclear pseudoinclusions should 
be large enough and well-delineated with darker outlines to be discriminated from 
superimposed erythrocytes and artefacts. Nuclear grooves are usually present in PTCs, but to 
be reliable enough they should be widespread and clear rather than being a focal change or an 
artificial appearance caused by overlapping cells. Hypochromasia/nuclear clearing is an 
alerting finding, however depending on technical issues it might be misleading on its own. 
Uniformly enlarged oval shaped nuclei are also important in the diagnosis.1,3,4 The patterns of 
cytologic atypia mimicking PTC, formation of papillae or caps, are described in the 
literature.1,4 Pseudopapillary formation as an architectural pitfall is well document by Majahan 
et al. 48 This study also stated that the presence of intranuclear cytoplasmic pseudoinclusions 
in parathyroid adenomas, not only overlaps with FN, but can also mimic PTC on aspirates.  
Psammoma bodies are quite specific for PTC; however dystrophic calcifications and dense 
colloid bodies should not be interpreted as psammoma bodies as these are almost never 
laminated in appearance in contrast to psammoma bodies. Another point is the amount and 
type of colloid that is usually scanty and of bubble-gum type in PTC. However, stromal 
degenerative fragments can mimic bubble-gum type colloid and large amounts of loose 
colloid may also be seen in PTC. Keeping in mind that all the cytological features cannot be 
present in each case one should be careful not to miss PTC; on the other hand, care is also 
needed not to overdiagnose nuclear and/or pattern atypia in benign entities as PTC.4 The two 
categories of the Bethesda System, “AUS/FLUS” and “suspicious for malignancy”, are 
present for these equivocal findings and the degree of atypia determines the appropriate 
choice in reporting.2  
Another primary thyroid tumour, which is frequently misdiagnosed as PTC or 
suspicious for PTC is hyalinizing trabecular tumour (HTT). It may also mimic MTC. 
Aspirates show oval to spindle-shaped cells with multiple intranuclear pseudoinclusions, in 
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loose groups. Nuclei are uniform with smooth contours, grooves are uncommon. Presence of 
a metachromatic acellular material surrounded by tumour cells in a radiating fashion is one of 
the characteristics of this lesion. However, unfortunately this material may be interpreted as 
amyloid or colloid. Papillary or sheet-like fragments are generally absent and if 
immunocytochemistry is available the membrane staining (instead of the normal nuclei 
staining) for MIB-1 can be a helpful hint for HTT.4,49  The difficulty of a cytological 
diagnosis of HTT is underlined by the fact that according to a recent review of the literature, 
60% of published cases of HTT in which a cytological diagnosis was included were 
misdiagnosed as suggestive, suspicious or positive for PTC. Of the remaining 40% of cases, 
6% were reported as PTC versus HTT; 10% as follicular neoplasms (FNs); 1% as MTC; 10% 
as AUS; and, finally, only 8% of cases were correctly identified as HTT by FNA. Although 
architectural features are diminished in cytological samples, they are not absent, and must be 
taken into account and correctly interpreted when making a diagnosis. 48 The absence of 
papillary structures and denuded fibrovascular stalks and the presence of elongated epithelial 
cells associated with acellular hyaline stroma are significant clues for HTT diagnosis. 49  
 
Medullary thyroid carcinoma 
Medullary thyroid carcinoma (MTC) is more aggressive than follicular derived 
neoplasms of the thyroid and is more frequently underdiagnosed than overdiagnosed. It is 
characterized by many single cells and loose tissue fragments; typically, follicular formation 
is not seen, and papillary structures are very rare. However, it may display nested/ trabecular/ 
loose microfollicular patterns, which could be misleading as follicular neoplasm, and may 
show oncocytic cytoplasm mimicking oncocytic follicular neoplasm. True oncocytes display 
centrally placed nuclei with macronucleoli which are unusual for MTC.1,4 MTC is one of the 
great mimickers of PTC; nuclear elongation, intranuclear pseudoinclusions, groove-like 
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formations, and nuclear membrane irregularity are some of the cytomorphologic features that 
can be seen in both malignancies. However, a predominantly dispersed cell population, 
neuroendocrine type chromatin, some binucleation, eccentric nuclei, and presence of both 
plasmacytoid and spindle cells helps to identify MTC. Immunohistochemical studies and/or 
serum calcitonin analysis can give the final diagnosis. Rarely, some situations such as  
regenerative/degenerative processes with abundant spindle cells can mimic MTC. The nature 
of the chromatin and the clinical history and other laboratory examination results can help in 
the differential diagnosis. Paragangliomas are also a mimicker of MTC but to distinguish 
these entities by cytomorphology alone is nearly impossible, clinical findings and 
immunohistochemistry are  needed.4 When amyloid is detected in thyroid FNA biopsies, 
MTC should be carefully searched for and excluded both by morphology and 
immunocytochemistry.4,50 The presence of amyloid can be a sign of primary or secondary 
amyloidosis (amyloid goitre) or can also accompany plasmacytomas and MALT lymphomas 
4,51. Due to its resemblance to dense colloid, recognizing amyloid on cytology slides may be 
difficult. Both amyloid and colloid are seen as metachromatic in Diff-Quick and blue-green-
pink-orange in PAP stains; amyloid looks more solid and hyaline-like than colloid. 4 The 
presence of amyloid may cause secondary inflammation, reactive changes and a giant cell 
reaction leading to an atypical/ suspicious diagnosis. 4,51  
 
Metastatic tumours 
Discussing the pitfalls in thyroid cytology, metastatic malignancies always should be 
kept in mind.  It is always a possibility in the presence of a thyroid nodule, especially in 
patients with known malignancy in other organs. Any cytomorphology picture, which is not 
typical for common primary thyroid tumours should alert us to this possibility4. Metastasis 
from adjacent anatomical regions to the thyroid (pharynx, larynx, oesophagus, mediastinum, 
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and regional lymph nodes) and distant ones sites are the most common.Lung, breast, skin 
(especially melanoma), colon, and kidney should be included in the differential diagnosis, 
particularly for some PTC and MTC variants and rarer tumours of thyroid2,4. However, 
distinguishing these entities by cytomorphology alone is nearly impossible as clinical findings 
and immunohistochemistry are needed. Immunocytochemistry can be applied in two steps. 
First, TTF-1, TTF-2, PAX8 or TG should be performed to show a primary thyroid origin of 
the tumour. After this step, if  required further organ-specific markers can be performed in the 
light of the clinical information to detect the primary origin of the tumour2,4. 
Molecular tests and usefulness in false positive causes of thyroid FNA  
Besides, cytomorphological, radiological, and clinical findings, molecular tests have a 
place in patient management to overcome the inherent limitations of thyroid cytology. 
Molecular studies using cytological materials have gained increasing importance  in recent 
years to decrease false positive rates and prevent unnecessary surgery52. According to the 
National Comprehensive Cancer Network guidelines, to gain a place in patient management 
for a molecular test the negative predictive value (NPV) should be >95% as a rule out test, 
whereas the positive predictive value (PPV) should be 95% as a rule in test to enable  
operations such as total thyroidectomy53. Currently some rule in and rule out  molecular tests 
are already in routine use especially in the USA  in patient management 53,54. A wide range of 
cytological material such as cell collection at R.O.S.E, cells obtained from slides in archive 
materials (air-dried slides and cell blocks) are suitable for use with the current molecular tests 
on the market53. For Category I/ND and Category II /Benign TBSRTC cases molecular 
analyses are not recommended in many guidelines, however, with the remarkable success of  
advances in molecular testing assays for point mutation analysis as well as chromosome 
rearrangements are already in use to tailor the management of indeterminate  thyroid cytology 
lesions, namely AUS/FLUS, SFN/FN and SFM categories55.  
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Molecular tests can be categorised as gene expression classifiers (GEC), gene mutational 
panels, targeted next-generation sequencing (tNGS)  and  combinations of mutation detection 
and miRNA expression These tests are used as both rule in and rule out tests56. Briefly, the 
main tests are: 
AFIRMA:  The microarray technology-based test Afirma GEC from Veracyte analyzes 167 
different mRNA profiles composed of two sets of genes (25 genes for less common and 142 
genes for the most common entities see in thyroid cancer). The test is validated as “rule out”, 
i.e. “to say negative for samples cytomorphologically interpreted as negative” with the high 
negative predictive value (NPV) (95% and 94%, respectively) in AUS/FLUS and SFN/FN 
cases. On the other hand, NPV ratios are as  low as 85% in the SFM category52, 56. 
ThyGenX/ ThyraMIR:  ThyGenX (Asuragen) is a genomic mutation-based test using the 
advances in  multiplexing analysis in cytology materials. This test, formerly known as the 
“seven gene test”, was modified by Interpace Diagnostics as a thyroid oncogene panel. More 
than 100 genetic alterations of 8 genes associated with thyroid cancer (including PTC, FTC, 
MTC and ATC) can be detected. The test was designed as a “rule-in” test  to detect 
malignancy in indeterminate lesions and a validation study to screen BRAF, RAS, HRAS, 
NRAS, PIK3CA point mutations, RET/PTC1, RET/PTC3, PAX8/PPAR reported with 88%, 
87% and 95% PPV ratios for AUS/FLUS, SFN/FN and SFM diagnostic categories, 
respectively52,56.  
ThyraMIR, was  developed  by Interpace Diagnostics to search for 10 different miRNAs. 
NPV and PPV for malignancy were reported as 94% and 74%. Although, these two tests can 
be used as separately, Interpace Diagnostics recommends ThyraMIR as a reflex test in the 
nodules that are shown to be negative by ThyGenX52,54. 
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When both tests are negative, residual ROM can reduce up to 6%. These tests have almost the 
same NPV ratios as  AFIRMA, besides the high PPV ratios, and therefore are acceptable as 
“rule in” and “rule out” tests 52. 
ThyroSeq TEST:  A NGS-based gene mutation and fusion panel that has been designed to 
detect 12 cancer genes and 284 mutational hot spots.  In 2014, an enhanced version was 
introduced to the market with DNA (14 genes and >1000 mutations) and RNA (42 fusions, 16 
genes) alterations. The study of Nikiforov et al. showed that ThyroSeq is a good “rule-out” 
test with the 98% NPV ratios, whereas PPV ratios were found between 40%-69% (a  high rate 
of false positives possibly being due to the expanded NGS-based mutational profile) which is 
not a promising as a “rule-in” test. Recently, same group released a validation study of a 
ThyroSeq v3 genomic classifier that analyzes 112 genes for various genetic alterations (point 
mutations, insertions/deletions, gene fusions, copy number alterations, and abnormal gene 
expressions). ThyroSeq v3 showed high accuracy for all common thyroid cancer types as well 
as parathyroid lesions. By adding copy number analyses, ThyroSeq v3 claimed  improved 
accuracy for Hurthle cell tumours52,54, 56, 57. 
BRAF v 600E mutation: BRAF V600E mutation is known to be >99% specific for diagnosis of 
thyroid cancer (particularly for PTC), therefore mutational positivity of BRAF V600E is 
meaningful when cytomorphological findings indicate an indeterminate cytology result. 
BRAF V600E testing is also useful in NIFTP diagnosis, since these tumours are follicular 
derived RAS-driven thyroid lesions and almost never show BRAF V600E mutations if strict 
morphological criteria for NIFTP are applied. When the strict diagnostic criteria of NIFTP are 
applied, the presence of a BRAF V600E mutation should therefore exclude a NIFTP tumour in 
FNA aspirates associated with the subtle nuclear changes of PTC with a very high degree of 
certainty58.  
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Medicolegal Implications 
The expectation of patients and clinicians is that thyroid FNA will work as an effective 
diagnostic test, but given its limitations, it is inevitable that false positive cytological 
diagnoses of malignancy will occur in thyroid FNA cytology. A recent survey of medicolegal 
claims against the NHS Litigation Authority for thyroid surgery in England in the period  
1995-2012 showed 223 claims related to thyroid surgery of which 22 cases related to 
diagnostic delay or incorrect diagnosis, many of which inevitably involve pathology or 
cytology59.In thyroid FNA cytology the interobserver and also intraobserver differences in 
diagnosis that are seen in routine clinical practice between a TBSRTC category VI/Thy 5 
diagnosis and TBSRTC category V/Thy 4 are frequently quite subjective and are often a 
matter of professional opinion among trained and experienced cytopathologists rather than a 
matter of fact. These differences can be readily explained by the known interobserver 
variation in the reporting of thyroid FNAC. For example in an interobserver study among  6 
experienced cytopathologists of 200 randomly selected thyroid FNA specimens using the UK 
Royal College of Pathologists Thyroid FNA Classification  the number of cases diagnosed as 
Thy 5 was mean 18.6 (range 8-23) and Thy 4  16.6 (range 8-26)60. Cibas and colleagues later 
showed using the 6 category Bethesda system that only 64.0% of diagnoses made by local 
cytopathologists and a central review panel of cytopathologists were concordant. In this study 
only 74.7% of intraobserver diagnoses were concordant when the same slides were reviewed 
blindly on a different occasion by the same cytopathologist. Concordance of central review 
panel of cytopathologists with local cytopathologists for the malignant TBSRTC category VI 
was 94% (n=51) and for suspicious for malignancy TBSRTC category V, 37% (n=38)61. 
Hence in this major study 6% of cases that were diagnosed as TBSRTC category VI 
(equivalent to Thy 5 in the UK) by local cytopathologists were downgraded on central 
cytopathology review. Since the risk of malignancy for TBSRTC category VI is less than 
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100%, patients need to be aware of the risk of malignancy and also the false negative risk in 
this category and a disclaimer about the risk of malignancy of each category can be presented 
in the cytology reports to inform  both patients and their surgeons. 
 
Conclusions 
The main role of thyroid FNAC is the triage of patients who actually require surgery, 
thus reducing the number of unnecessary thyroidectomies and possible complications. 62 
Ultrasound image features must be taken into account to plan appropriate patient management 
in a multidisciplinary approach to patient management. A cytology result with suspicious or 
malignant findings in the presence of a nodule with benign ultrasound  features should be 
carefully studied to avoid a false positive diagnosis. As a cytological diagnosis of malignancy 
may require aggressive surgical treatment, including total  thyroidectomy with possible  
central neck dissection, the correct FNA diagnosis is important to guide proper management 
of patients and to avoid overtreatment. In some cases if there is still uncertainty cell block 
immunohistochemistry of  the current specimen or of a repeat thyroid FNAC and/or core 
biopsy will allow confirmation of the presence of malignancy and also the exact nature of the 
malignancy (e.g. medullary carcinoma or poorly differentiated carcinoma) . Molecular testing 
including for BRAF V600E mutation may also be helpful. All centres should audit their own 
practice of both thyroid cytology and histology to identify the risk of malignancy for all 
subcategories of thyroid FNAC, whether using TBSRTC, UK RCPath Thy or another 
internationally recongised terminology system bearing also in mind that the histopathological 
diagnosis may also be subject to significant interobserver variation62. It is important to note 
that an accurate diagnosis by FNA crucially depends on the sample being representative and 
adequate in cellularity, appropriately processed, and stained, in order to provide high-quality 
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preparations for assessment. When these conditions are not met, repeat sampling with or 
without on-site assessment should be considered prior to surgical management.  
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Legend for figures 
Figure 1. Reactive cyst lining cells with elongated cytoplasm showing nuclei with some 
irregular contours (MGG, 40X).  
 
Figure 2. Reactive epithelial follicular and histiocytic cells with overlapping due smear 
artefact in case of granulomatous thyroiditis (MGG, 20X). 
 
Figure 3. Cell debris in background of smear of thyroiditis simulating necrosis (MGG, 10X). 
 
Figure 4. Atypical oncocytes in Hashimoto thyroiditis. Note presence of lymphocytes. 
(MGG, 40X). 
 
Figure 5. Florid lymphoid phase of Hashimoto thyroiditis simulating a low-grade lymphoma. 
Most of these cases need flow cytometry for the definitive diagnosis. (MGG, 40X) 
 
Figure 6. Pseudo microfollicular appearance create by the presence of clots (PAP, 20X). 
 
